Biotech Values

[ciotera]

Agreed. The possibility that SVR24 might not be the universally accepted efficacy metric for all-oral regimens complicates things immensely from an investment standpoint. Assuming that ABT’s result in #msg-74608528 was not a fluke, I predict that it will take a while before all this gets sorted out.

In light of this uncertainty, it makes sense that BMY continues to invest in lambda.